A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.

Hdl Handle:
http://hdl.handle.net/10144/17743
Title:
A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.
Authors:
Janssens, B; Van Herp, M; Goubert, L; Chan, S; Uong, S; Nong, S; Socheat, D; Brockman, A; Ashley, E A; Van Damme, W
Journal:
Tropical Medicine & International Health
Abstract:
OBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.
Affiliation:
Médecins Sans Frontières, Phnom Penh, Cambodia. b.janssens@bigfoot.com
Publisher:
Wiley-Blackwell
Issue Date:
Feb-2007
URI:
http://hdl.handle.net/10144/17743
DOI:
10.1111/j.1365-3156.2006.01786.x
PubMed ID:
17300633
Additional Links:
http://www.blackwell-synergy.com/loi/tmi
Language:
en
ISSN:
1360-2276
Appears in Collections:
Malaria

Full metadata record

DC FieldValue Language
dc.contributor.authorJanssens, B-
dc.contributor.authorVan Herp, M-
dc.contributor.authorGoubert, L-
dc.contributor.authorChan, S-
dc.contributor.authorUong, S-
dc.contributor.authorNong, S-
dc.contributor.authorSocheat, D-
dc.contributor.authorBrockman, A-
dc.contributor.authorAshley, E A-
dc.contributor.authorVan Damme, W-
dc.date.accessioned2008-02-07T16:56:24Z-
dc.date.available2008-02-07T16:56:24Z-
dc.date.issued2007-02-
dc.identifier.citationA randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. 2007, 12 (2):251-9 Trop. Med. Int. Healthen
dc.identifier.issn1360-2276-
dc.identifier.pmid17300633-
dc.identifier.doi10.1111/j.1365-3156.2006.01786.x-
dc.identifier.urihttp://hdl.handle.net/10144/17743-
dc.description.abstractOBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.en
dc.language.isoenen
dc.publisherWiley-Blackwell-
dc.relation.urlhttp://www.blackwell-synergy.com/loi/tmi-
dc.rightsArchived on this site with the kind permission of Wiley-Blackwellen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAnemiaen
dc.subject.meshAntimalarialsen
dc.subject.meshArtemisininsen
dc.subject.meshCambodiaen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshGenome, Protozoanen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshMalaria, Falciparumen
dc.subject.meshMalaria, Vivaxen
dc.subject.meshMaleen
dc.subject.meshMefloquineen
dc.subject.meshMiddle Ageden
dc.subject.meshQuinolinesen
dc.subject.meshRecurrenceen
dc.subject.meshSesquiterpenesen
dc.subject.meshTreatment Outcomeen
dc.titleA randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.en
dc.contributor.departmentMédecins Sans Frontières, Phnom Penh, Cambodia. b.janssens@bigfoot.comen
dc.identifier.journalTropical Medicine & International Healthen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.